Publicaciones en colaboración con investigadores/as de Columbia University (8)

2024

  1. Maintenance therapy for CTCL: importance for prevention of disease progression

    Leukemia and Lymphoma

2023

  1. International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study

    Journal of the American Academy of Dermatology, Vol. 88, Núm. 4, pp. 935-937

2021

  1. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma

    Journal of Investigative Dermatology, Vol. 141, Núm. 6, pp. 1601-1604.e2

  2. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

2020

  1. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

    Nature Medicine, Vol. 26, Núm. 12, pp. 1865-1877

  2. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    European Journal of Cancer, Vol. 133, pp. 120-130

  3. The course of mycosis fungoides under cytokine pathway blockers: A multicentre analysis of real-life clinical data

    Acta Dermato-Venereologica, Vol. 100, Núm. 16, pp. 1-7

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566